Drug-induced QT interval shortening: An emerging component in integrated assessment of cardiac safety of drugs

Journal of Electrocardiology

Volumn 43, Issue 5, 2010, Pages 386-389

  Shah, Rashmi R ^a   Bjerregaard, Preben ^b   Gussak, Ihor ^c,d  

^a Rashmi Shah Consultancy Ltd   (United Kingdom)

^b WASHINGTON UNIVERSITY   (United States)

^c NewCardio Inc   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; LAMOTRIGINE; LEMAKALIM; MALLOTOXIN; NICORANDIL; NS 1643; PINACIDIL; POTASSIUM CHANNEL AFFECTING AGENT; PRIMIDONE; RUFINAMIDE; UNCLASSIFIED DRUG; DRUG;

CARDIOVERSION; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SHORT QT INTERVAL; TREATMENT INDICATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG SCREENING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; LONG QT SYNDROME; PHENOTYPE; SYNDROME; UNITED STATES;

ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG EVALUATION, PRECLINICAL; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; SYNDROME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952118531     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2010.06.008     Document Type: Editorial

References (53)

1. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of Q-T interval and sudden death. Am Heart J 1957;54:59.
2. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare dell'ete'pediatrica [Italian]. Clin Pediatr (Bologna) 1963;45:656.
3. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc 1964;54:103.
4. Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet J Rare Dis 2008;3:18.
5. Shah RR. The significance of QT interval during drug development. Br J Clin Pharmacol 2002;54:188.
6. Shah RR. Cardiac repolarisation and drug regulation: Assessing cardiac safety 10 years after the CPMP guidance. Drug Saf 2007;30:1093.
7. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: Potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145.
8. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004;82:182.
9. Aerssens J, Paulussen AD. Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 2005;6:259.
10. Chevalier P, Bellocq C, Millat G, et al. Torsades de pointes complicating atrioventricular block: Evidence for a genetic predisposition. Heart Rhythm 2007;4:170.
11. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-Associated torsades de pointes. Heart Rhythm 2007;4:603.
12. Committee for Proprietary Medicinal Products: Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Noncardiovascular Medicinal Products (CPMP/986/96). EMEA: London, 17 December 1997. http://www.fda.gov/ohrms/dockets/ac/03/briefing/ pubs%5Ccpmp.pdf [Accessed on 27 April 2010].
13. International Conference on Harmonization Note for Guidance on the Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (ICH S7B) (CHMP/ICH/423/02). EMEA: London, 25 May 2005a. http://www.emea.eu.int/pdfs/human/ich/042302en.pdf [Accessed on 27 April 2010].
14. International Conference on Harmonization Note for Guidance on the Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (ICH E14) (CHMP/ICH/2/04). EMEA: London, 25 May 2005b. http://www.emea.eu.int/pdfs/human/ ich/000204en.pdf [Accessed on 27 April 2010].
15. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: A new clinical syndrome? Cardiology 2000;94:99.
16. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: A familial cause of sudden death. Circulation 2003;108:965.
17. Makarov LM, Chuprova SN, Kiseleva II. QT interval shortening in families with history of sudden death at young age [in Russian]. Kardiologiia 2004;44:51.
18. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004;109:30.
19. Bellocq C, van Ginneken AC, Bezzina CR, et al.Mutation in the KCNQ1 gene leading to the short QT interval syndrome. Circulation 2004;109:2394.
20. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005;96:800.
21. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss of function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442.
22. Bjerregaard P, Nallapaneni H, Gussak I. Short QT interval in clinical practice. J Electrocardiol 2010;43:390.
23. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J 1993;70:43.
24. Viskin S, Zeltser D, Ish-Shalom M, et al. Is idiopathic ventricular fibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. Heart Rhythm 2004;1:587.
25. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV. Prevalence and prognostic significance of short QT interval in a middle-Aged Finnish population. Circulation 2007;116:714.
26. de La Coussaye JE, Eledjam JJ, Bruelle P, et al. Electrophysiologic and arrhythmogenic effects of the potassium channel agonist BRL 38227 in anesthetized dogs. J Cardiovasc Pharmacol 1993;22:722.
27. Tosaki A, Szerdahelyi P, Engelman RM, Das DK. Potassium channel openers and blockers: Do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J Pharmacol Exp Ther 1993;267:1355.
28. Robert E, Delye B, Aya G, et al. Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): A high-resolution mapping study on rabbit heart. J Cardiovasc Pharmacol 1997;29:109.
29. Robert E, Aya AG, de la Coussaye JE, et al. Dispersion-based reentry: Mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. Am J Physiol 1999;276(2 Pt 2):H413.
30. Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular wedge model of short QT syndrome. Circulation 2004;110:3661.
31. Seebohm G, Pusch M, Chen J, Sanguinetti MC. Pharmacological activation of normal and arrhythmia-Associated mutant KCNQ1 potassium channels. Circ Res 2003;93:941.
32. Kang J, Chen XL, Wang H, et al. Discovery of a small molecule activator of the human ether-Ago-go-related gene (hERG) cardiac K+ channel. Mol Pharmacol 2005;67:827.
33. Zhou J, Augelli-Szafran CE, Bradley JA, et al. Novel potent human ether-A-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005;68:876.
34. Casis O, Olesen SP, Sanguinetti MC. Mechanism of action of a novel human ether-A-go-go-related gene channel activator. Mol Pharmacol 2006;69:658.
35. Hansen RS, Olesen SP, Grunnet M. Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart. J Pharmacol Exp Ther 2007;321:996.
36. Gordon E, Lozinskaya IM, Lin Z, et al. 2-[2-(3,4-Dichloro-phenyl)-2,3- dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-A-go-go-related gene potassium channels. Mol Pharmacol 2008;73:639.
37. Lu HR, Vlaminckx E, Hermans AN, et al. Predicting druginduced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol 2008;154:1427.
38. Holbrook M, Malik M, Shah RR, Valentin JP. Drug-induced shortening of the QT/QTc interval: An emerging safety issue in drug research and development? J Pharmacol Toxicol Methods 2009;59:21.
39. Carducci B, Hedges JR, Beal JC, Levy RC, Martin M. Emergency phenytoin loading by constant intravenous infusion. Ann Emerg Med 1984;13:1027.
40. Wyte CD, Berk WA. Severe oral phenytoin overdose does not cause cardiovascular morbidity. Ann Emerg Med 1991;20:508.
41. Saner HE, Lange HW, Pierach CA, Aeppli DM. Relation between serum digoxin concentration and the electrocardiogram. Clin Cardiol 1988;11:752.
42. Duraković Z, Smalcelj A, Kvarantan M, et al. Is there a correlation between changes in the electrocardiogram and high serum digoxin levels in the aged? [in Croatian]. Lijec Vjesn 1990;112:208.
43. Danielsson BR, Lansdell K, Patmore L, Tomson T. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 2003;55:147.
44. Wang L, Wible BA, Wan X, Ficker E. Cardiac glycosides as novel inhibitors of human ether-A-go-go-related gene channel trafficking. J Pharmacol Exp Ther 2007;320:525.
45. Watanabe O, Okumura T, Takeda H, et al. Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block. Pacing Clin Electrophysiol 1999;22 (4 Pt 1):686.
46. DeSilvey DL, Moss AJ. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. Ann Intern Med 1980;93:53.
47. Aurlien D, Taubøll E, Gjerstad L. Lamotrigine in idiopathic epilepsy-increased risk of cardiac death? Acta Neurol Scand 2007;115:199.
48. Aurlien D, Leren TP, Taubøll E, Gjerstad L. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 2009;18:158.
49. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008;66:396.
50. Fichet J, Genee O, Pierre B, Babuty D. Fatal QT interval. Am J Emerg Med 2008;26:739.
51. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 1998;9:1114.
52. Kijtawornrat A, Panyasing Y, Del Rio C, Hamlin RL. Assessment of ECG interval and restitution parameters in the canine model of short QT syndrome. J Pharmacol Toxicol Methods 2010 (manuscript in press) [Feb 12. Epub ahead of print].
53. Shah RR. Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol 2010;159:58.